https://www.selleckchem.com/products/U0126.html
7%, 95% CI 97.6-111.8%, P=0.015). The mean ODSS was 2.0 (95% CI 0.8-3.2) which is identical to the baseline score following completion of the fSCIG trial, the P-value for non-inferiority being 0.0001. The secondary variables of impairment, function and quality of life at follow-up all were non-inferior to baseline values (P≤0.046). fSCIG seems feasible and effective for long-term maintenance treatment in patients with MMN. fSCIG seems feasible and effective for long-term maintenance treatment in patients with MMN.Reductive cleavage of
Мне нравится
Комментарий
Перепост
